tegaserod: Clinical Trials

10 completed, 4 terminated. 14 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	14	Completed 10, Terminated 4
Phase 2	1	Terminated 1

Follow tegaserod: new trials by email Literature Review of tegaserod trials Research Report on tegaserod

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. Tegaserod - Opioid-induced Constipation	Phase 3	Terminated	Novartis	11	2007-02-01	2012-04-20
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain. Tegaserod - Opioid-induced Constipation	Phase 3	Terminated	Novartis	360	2006-11-01	2012-05-01
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain Tegaserod - Constipation	Phase 2 / Phase 3	Terminated	Novartis	670	2006-07-01	2012-04-20
The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn. Tegaserod - Dyspepsia	Phase 3	Completed	Novartis	60	2005-04-01	2008-02-01
The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia. Tegaserod - Heartburn, Dyspepsia	Phase 3	Completed	Novartis	24	2005-04-01	2007-10-10
An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation Tegaserod - Constipation	Phase 3	Completed	Novartis	600	2005-02-01	2008-02-01
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS) Tegaserod - Constipation Predominant, Irritable Bowel Syndrome (IBS-C)	Phase 3	Terminated	Novartis Pharmaceuticals	20	2004-11-01	2012-04-20
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Tegaserod - Dyspepsia	Phase 3	Completed	Novartis	359	2004-09-01	2008-02-01
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia Tegaserod - Dyspepsia	Phase 3	Completed	Novartis	423	2004-09-01	2008-02-01
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia Tegaserod - Dyspepsia	Phase 3	Completed	Novartis	1296	2004-05-01	2016-11-18
Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation. Tegaserod - Chronic Constipation	Phase 3	Completed	Novartis	1026	2004-03-01	2008-02-01
Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia Tegaserod - Dyspepsia	Phase 3	Completed	Novartis	1296	2004-01-01	2008-02-01
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Tegaserod - Gastroesophageal Reflux Disease (GERD)	Phase 3	Completed	Novartis	30	2004-01-01	2008-01-28
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs). Tegaserod - Gastroesophageal Reflux Disease (GERD)	Phase 3	Completed	Novartis	54	2003-06-01	2008-01-28

Conditions studied

Dyspepsia (6)  ·  Constipation (4)  ·  Opioid-Induced Constipation (3)  ·  Gastroesophageal Reflux (2)  ·  Heartburn (2)  ·  Irritable Bowel Syndrome (1)

Sponsors

Novartis (13)  ·  Novartis Pharmaceuticals (1)

Countries

United States (12)  ·  China (1)  ·  Egypt (1)  ·  Singapore (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  Venezuela (1)

Results publications

PMID 18561877, PMID 18616658